MANE

Veradermics, Incorporated

138.78

USD

+10.18

+7.92%

Nov 06, 15:59 UTC -5

Closed

After-Market

139.00

+0.22

+0.16%

Veradermics, Incorporated (MANE) Earnings

MANE Earnings Reports

Positive Surprise Ratio

MANE beat 1 of 2 last estimates.

50%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Veradermics, Incorporated earnings per share and revenue

On Aug 11, 2026, MANE reported earnings of -0.57 USD per share (EPS) for Q2 26, beating the estimate of -0.66 USD, resulting in a 12.19% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.46

Actual

-$1.33

Surprise

+9.05%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Genmab A/S ADS

Report Date

Nov 05, 2026 For Q3 26

Estimate

$3.86

Actual

$5.64

Surprise

+46.11%

Certara, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.09

Surprise

-0.88%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Corvus Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.20

Actual

-$0.22

Surprise

-7.06%

Ginkgo Bioworks Holdings, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.87

Actual

-$0.64

Surprise

+27.17%

Lexicon Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.05

Actual

-$0.03

Surprise

+49.41%

Tectonic Therapeutic, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.35

Actual

-$1.08

Surprise

+20.37%

SAB Biotherapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.24

Surprise

+12.85%

FAQ

What were Veradermics, Incorporated's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Veradermics, Incorporated reported EPS of -$0.57, beating estimates by 12.19%, and revenue of $0.00, 0% as expectations.

How did the market react to Veradermics, Incorporated's Q2 2026 earnings?

The stock price moved down -1.63%, changed from $110.75 before the earnings release to $108.95 the day after.

When is Veradermics, Incorporated expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Veradermics, Incorporated's next earnings report?

Based on -- analysts, Veradermics, Incorporated is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.